Výsledky vyhledávání - "Masaru Hirano"

New paradigm for expediting drug development in Asia

Autor: Masaru Hirano, Wataru Honma, Sylvia Zhao, Iris Rajman

Publikováno v: Drug Discovery Today. 25:491-496

Some Asian regulators currently require Phase I data in Asians before joining global Phase II/III trials. Here, we discuss inherent limitations of Phase I ethnic sensitivity studies (ESS) to identify potential interethnic differences. We review recen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8850a98b329019fb494c3adb14bab24f
https://doi.org/10.1016/j.drudis.2019.12.013

Zobrazit plný text záznamu

Novel deletion in glycoprotein G forms a cluster and causes epidemiologic spread of herpes simplex virus type 2 infection

Autor: Tohru Daikoku, Kimiyasu Shiraki, Takashi Kawana, Masaru Hirano, Kazuhiro Horiba

Publikováno v: Journal of Medical Virology. 85:1818-1828

The herpes simplex virus type 2 (HSV-2) glycoprotein G (gG-2) gene of 106 clinical isolates was analyzed and six isolates were identified with 63 nucleotides comprising 21 amino acids (aa) deleted in the immunodominant region. Compared with strain HG

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::497fbbc5aa36f80ee26678ccc2f07de6
https://doi.org/10.1002/jmv.23668

Zobrazit plný text záznamu

Relationship between Crystal Polymorphism and Solution Structure of an Imidazopyridine Derivative Developed as a Drug Substance for Osteoporosis

Autor: Hiroto Tue, Rui Tamura, Masaru Hirano, Kouji Machiya, Hiroshi Ooshima, Koichi Igarashi

Publikováno v: JOURNAL OF CHEMICAL ENGINEERING OF JAPAN. 42:204-211

An imidazopyridine derivative developed for osteoporosis treatment (a bone proton pump inhibitor, abbreviated BPPI) was crystallized in two kinds of alcohol. Two crystal polymorphs appeared: an unstable B01 form and a stable B02 form. The B01 form wa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0499542e98242042be58b783d06a890
https://doi.org/10.1252/jcej.08we299

Zobrazit plný text záznamu

The Quantitative Prediction of CYP-mediated Drug Interaction by Physiologically Based Pharmacokinetic Modeling

Autor: Toshihiko Ikeda, Masaru Hirano, Motohiro Kato, Yuichi Sugiyama, Kunihiro Yoshisue, Hitoshi Sato, Yoshihisa Shitara

Publikováno v: Pharmaceutical Research. 25:1891-1901

The objective is to confirm if the prediction of the drug-drug interaction using a physiologically based pharmacokinetic (PBPK) model is more accurate. In vivo Ki values were estimated using PBPK model to confirm whether in vitro Ki values are suitab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29207f6ac188a5cf943c3ae59fb178dd
https://doi.org/10.1007/s11095-008-9607-2

Zobrazit plný text záznamu

SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers

Autor: H Uchimaru, Masaru Hirano, Hiroyuki Kusuhara, Yuichi Sugiyama, Miyuki Kimura, Kazuya Maeda, Shun Higuchi, S Suwannakul, Shin Irie, Ichiro Ieiri, K Hashimoto, H Fujino

Publikováno v: Clinical Pharmacology & Therapeutics. 82:541-547

To investigate the contribution of genetic polymorphisms of SLCO1B1 and ABCG2 to the pharmacokinetics of a dual substrate, pitavastatin, 2 mg of pitavastatin was administered to 38 healthy volunteers and pharmacokinetic parameters were compared among

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a21ef9ce1857ad9bdf2144fb8146f5a
https://doi.org/10.1038/sj.clpt.6100190

Zobrazit plný text záznamu

Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor

Autor: Gangadhar Sunkara, Pascale Pinot, Masaru Hirano, Sam Rebello, Tapan Majumdar, Parasar Pal, Jin Chen, GangaRaju Golla, Tsu-Han Lin, Dan Meyers

Publikováno v: Clinical pharmacokinetics. 54(7)

Pradigastat, a diacylglycerol acyltransferase1 inhibitor, is being developed for the treatment of familial chylomicronemia syndrome. The primary objective of this clinical study was to evaluate the effect of renal impairment on the pharmacokinetics o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::797688ee0cef2c7455f3785942991edf
https://pubmed.ncbi.nlm.nih.gov/25633714

Zobrazit plný text záznamu

Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril

Autor: Akiharu Fujino, Hiroyuki Kusuhara, Kuninobu Yasuda, Ichiro Ieiri, Takao Watanabe, Yoshiaki Kitamura, Kenji Otsubo, Masaru Hirano, Kazuya Maeda, Yuichi Sugiyama, Hiroaki Fujiwara

Publikováno v: Clinical Pharmacology & Therapeutics. 79:427-439

Objective Recent reports have shown that genetic polymorphisms in organic anion transporting polypeptide (OATP) 1B1 have an effect on the pharmacokinetics of drugs. However, the impact of OATP1B1*1b alleles, the frequency of which is high in all ethn

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba52609be2b222e597a4e28afbf1f208
https://doi.org/10.1016/j.clpt.2006.01.011

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání